Harris Interactive has been digging into physicians' response to drug brands, therapeutic area by therapeutic area, racking up more evidence for an emotional variable in the doctor-drug trust equation.
The U.K.'s cost-effectiveness watchdogs must really like Eliquis. The new blood thinner from Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) won a thumbs-up for stroke prevention.
For the first time in 12 years, the U.S. has a new IUD approved for commercial use, and Bayer is bringing it to market in early February.
Bayer has another foe in its battle to defend the contraceptive pill Yasmin. Switzerland's biggest insurer, CSS, is backing a woman's claims against the German company, joining in her lawsuit that alleges Yasmin triggered her disabling pulmonary embolism.
Novartis is one step closer to marketing Lucentis in a new group of patients. The National Institute for Health and Clinical Excellence officially changed its mind on the Swiss drugmaker's eye treatment, recommending the pricey injection for use in diabetics.
French regulators are tightening the purse strings on later-generation contraceptives--and studying limits on their use. Acting on concerns that the pills carry a higher risk of blood clots than older birth-control brands, the country's health ministry will stop paying for third-generation pills beginning March 31.
Pfizer's animal health unit may be worth $20 billion, and that is the conundrum.
After sources said Bayer was halting its blood glucose meter sale, The Wall Street Journal reports that Sanofi remains in talks with the German company over a deal that could be worth about $1.5 billion.
European regulators have given the thumbs-up to Bayer's Jaydess, a low-dose controlled-release hormonal contraceptive.
When Bayer agreed to buy U.S.-based vitamin-and-OTC drug maker Schiff ($SHF), the company's reasoning went something like this: Let's supplement our risky pharma business with some steady, reliable, low-risk revenue. It's less profitable and less sexy, but sometimes, less can be more.